RMD

ResMed|NYSE · Health Care Equipment · Health Care

Previous close

228.25

Change

−1.19 / −0.52%

FinDog View

Bullish

52-Week Range

180.27 – 284.87

P/E (TTM)

21.6

Forward P/E

17.4

Based on consensus earnings for the next 12 months

Market Cap

$32.9B

+3.58%

S&P 500 −2.41% over same period

Volume / Avg Volume

1.1M / 1.2M

0.88× average

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 20.91M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q4 Quarter ended 2026-06	2026-07-07	$5.7B	2.95 / 2.92	−6.33%	Read analysis →
FY2026 Q3 Quarter ended 2026-03	2026-04-30	$1.4B	2.86 / 2.82	−4.11%	Pending
FY2026 Q2 Quarter ended 2025-12	2026-01-29	—	— / —	+0.27%	Pending
FY2026 Q1 Quarter ended 2025-09	2025-10-30	—	— / —	−2.13%	Pending
FY2025 Q4 Quarter ended 2025-06	2025-07-31	—	— / —	+2.67%	Pending
FY2025 Q3 Quarter ended 2025-03	2025-04-24	$1.3B	2.48 / —	−0.09%	Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 10 of its 5-year rangeCheap

5-year range 19.7 – 35.2 · Median 28.1

Last 4 quarters: $700M in buybacks + $350M in dividends, 3.19% of market cap combined

P/E (TTM)

21.6

P/B

5.0

P/S

5.8

Dividend Yield

1.25%

Earnings Reaction

Over the last 6 reports, the stock moved ±2.6% on average on the first trading day after, rising 2 times

Most recent −6.33%

Volatility & Correlation

1-year beta 0.43 · Correlation with S&P 500 0.19Low beta

Annualized volatility 29% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 5 · $5.3MNet selling $5.3M

09-08Farrell Michael J.Chairman and CEOSell$1.1M4,991 shares · Avg price 222.44
09-02FARRELL PETER CDirectorSell$0.23M970 shares · Avg price 234.73
08-07Farrell Michael J.Chairman and CEOSell$1.0M4,991 shares · Avg price 205.69
08-05FARRELL PETER CDirectorSell$1.8M8,000 shares · Avg price 225.00
07-07Farrell Michael J.Chairman and CEOSell$1.1M4,991 shares · Avg price 218.55

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q4	1.46	+8.6%	58.8%	0.45	0.38	0.40	2.64
FY2026 Q3	1.43	+10.8%	62.2%	0.50	0.40	0.52	2.74
FY2026 Q2	1.42	+11.0%	61.8%	0.49	0.39	0.31	2.68
FY2026 Q1	1.34	+9.1%	61.5%	0.45	0.35	0.41	2.37
FY2025 Q4	1.35	+10.2%	60.8%	0.45	0.38	0.51	2.58
FY2025 Q3	1.29	+7.9%	59.3%	0.43	0.37	0.56	2.48
FY2025 Q2	1.28	+10.3%	58.6%	0.42	0.34	0.29	2.34
FY2025 Q1	1.22	+11.1%	58.6%	0.39	0.31	0.31	2.11
FY2024 Q4	1.22	+9.0%	58.5%	0.38	0.29	0.42	1.97
FY2024 Q3	1.20	+7.2%	57.9%	0.37	0.30	0.38	2.04
FY2024 Q2	1.16	+12.5%	55.6%	0.28	0.21	0.25	1.42
FY2024 Q1	1.10	+16.0%	54.4%	0.29	0.22	0.26	1.49

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
RMD	ResMed\|	$32.9B	21.6	+8.6%	58.8%	+3.58%	Bullish
LLY	Lilly (Eli)	$1.07T	39.9	+47.7%	85.8%	−3.83%	Bullish	Compare
JNJ	Johnson & Johnson	$644B	30.6	+6.6%	68.2%	+1.87%	Bullish	Compare
ABBV	AbbVie	$464B	73.7	+10.2%	74.7%	+4.87%	Neutral	Compare
MRK	Merck & Co.	$358B	112.2	+5.1%	73.5%	+6.57%	Neutral	Compare
UNH	UnitedHealth Group	$337B	23.9	+0.4%	88.1%	−5.15%	Neutral	Compare
TMO	Thermo Fisher Scientific	$240B	34.4	+10.5%	—	+10.75%	Bullish	Compare
AMGN	Amgen	$203B	23.3	+9.5%	72.0%	−10.26%	Neutral	Compare
GILD	Gilead Sciences	$183B	—	+10.2%	79.8%	+6.31%	Neutral	Compare

The View in One Line

Gross margin of 62.2% is relatively high, revenue of $1.43 billion, multiple institutions upgraded ratings, stock up 3.58% for the month, cautiously bullish.

Updated 2026-09-16

Key Events

09-01Capital Actions
ResMed Signs $450 Million Accelerated Share Repurchase Agreement with Citi
On August 31, ResMed entered a $450 million accelerated share repurchase agreement with Citi, with payment on September 3 and settlement expected in December.Source ↗
08-17Governance
ResMed Changes Auditor and Adjusts Board
ResMed dismissed KPMG and appointed PwC as auditor for fiscal 2027; director Ronald Taylor will retire at the November 18 annual meeting, and Carol Burt will become lead independent director.Source ↗
08-06Capital Actions
ResMed Raises Quarterly Dividend 10% to $0.66 per Share
ResMed declared a quarterly cash dividend of $0.66 per share, up 10% from the prior quarter, payable September 24 to shareholders of record August 20.Source ↗
04-30Capital Actions
ResMed Reports Quarterly Results and Declares $0.60 Per Share Dividend
ResMed reported results for the quarter ended March 31, 2026, and declared a quarterly cash dividend of $0.60 per share, with a May 14 record date and June 18 payment date.Source ↗
04-30Management Change
ResMed CFO Retires, Aaron Bloomer Succeeds
Brett Sandercock will step down as CFO on May 4, 2026 to become an advisor, with Aaron Bloomer succeeding him the same day at a base salary of $725,000.Source ↗

Key Financial Trends

Quarterly Revenue ($B)1.5

Gross Margin58.8%

Free Cash Flow ($B)0.4